<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="51742">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02432599</url>
  </required_header>
  <id_info>
    <org_study_id>APACH1</org_study_id>
    <nct_id>NCT02432599</nct_id>
  </id_info>
  <brief_title>Interest of the F18-choline as a Second Line of the Tracer for Detection of Parathyroid Adenomas</brief_title>
  <acronym>APACH1</acronym>
  <official_title>Interest of the F18-choline as a Second Line of the Tracer for Detection of Parathyroid Adenomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Francois Baclesse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Francois Baclesse</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The rationale for the proposed pilot study is to investigate the ability of PET-CT with
      F18-choline to detect and locate the parathyroid adenoma in patients with primary
      hyperparathyroidism and negative or non-contributory MIBI (Tc-99m sestamibi) and cervical
      ultrasound, in order to avoid unnecessary bilateral cervical exploration.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity (ability to identify and visualize the parathyroid adenoma)</measure>
    <time_frame>Up to 2 months</time_frame>
    <description>Sensitivity of PET-CT with F18-choline (FCH) to identify and visualize the parathyroid adenoma in patients with primary hyperparathyroidism and negative or non-contributory parathyroid scintigraphy MIBI and cervical ultrasound</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Hyperparathyroidism</condition>
  <arm_group>
    <arm_group_label>F18-choline PET</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>F18-choline PET examination will be performed before surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>F18-choline PET examination</intervention_name>
    <description>F18-choline PET examination will be performed before surgery</description>
    <arm_group_label>F18-choline PET</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient aged 18 years or more;

          -  Patient with a primary hyperparathyroidism and witj a negative or non-contriburatory
             MIBI parathyroid scintigraphy and neck ultrasonography, for which surgical resection
             is planned;

          -  Confirmation of the diagnosis of primary hyperparathyroidism on laboratory tests

          -  Affiliate to a social security system;

          -  Patient written informed consent.

        Exclusion Criteria:

          -  Patient deprived of liberty, under guardianship;

          -  Any medical or psychological condition witch could compromise the capacity of the
             patient to participate in the study;

          -  Pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Elisabeth QUAK, MD</last_name>
    <phone>0231455050</phone>
    <email>e.quak@baclesse.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jean-Michel GRELLARD, Project Manager</last_name>
    <phone>(+33) 2 31 45 50 02</phone>
    <email>jm.grellard@baclesse.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicolas AIDE, Pr</last_name>
      <email>aide-n@chu-caen.fr</email>
    </contact>
    <investigator>
      <last_name>Nicolas AIDE, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yves REZNIK, Pr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Fran√ßois Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisabeth QUAK, MD</last_name>
      <email>e.quak@baclesse.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Elisabeth QUAK, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Renaud CIAPPUCCINI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephane BARDET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 2, 2016</lastchanged_date>
  <firstreceived_date>April 29, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>F18-choline</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adenoma</mesh_term>
    <mesh_term>Hyperparathyroidism</mesh_term>
    <mesh_term>Parathyroid Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Choline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
